This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Early Ablation Therapy for the Treatment of Ischemic Ventricular Tachycardia in Patients With Implantable Cardioverter Defibrillators (ASPIRE)

This study has been terminated.
Information provided by (Responsible Party):
Biosense Webster, Inc. Identifier:
First received: March 16, 2012
Last updated: May 13, 2017
Last verified: May 2017
The purpose of this study is to determine if early ablation (i.e., ablation of ventricular tachycardia in patients with infrequent VT episodes) is more effective than medical therapy alone for the treatment of ischemic ventricular tachycardia in patients with Implantable Cardioverter Defibrillators (ICDs) who continue to have episodes of ventricular tachycardia despite drug therapy.

Condition Intervention Phase
Ventricular Tachycardia Ischemic Drug: Drug Treatment Device: Catheter Ablation Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Early Ablation Therapy for the Treatment of Ischemic Ventricular Tachycardia in Patients With Implantable Cardioverter Defibrillators

Resource links provided by NLM:

Further study details as provided by Biosense Webster, Inc.:

Primary Outcome Measures:
  • Percentage of Subjects Who Had Hospitalization for Ventricular Tachycardia (VT) Related Causes/Events [ Time Frame: From one month to 2 years follow up ]
    The hospital admission date must occur after completing the 1-month follow-up visit for the event to be considered an effectiveness failure.

  • Cardiac-related Death [ Time Frame: 2 years follow up ]
    Subjects with cardiac-related death

Enrollment: 15
Actual Study Start Date: June 1, 2012
Study Completion Date: March 19, 2014
Primary Completion Date: March 19, 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Treatment Group
This group receives radiofrequency catheter ablation and drug treatment.
Device: Catheter Ablation
Radiofrequency catheter ablation and Class I and III antiarrhythmic drug treatment.
Experimental: Control Group
This group receives only drug treatment.
Drug: Drug Treatment
Class I and III antiarrhythmic drug treatment.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subject must be drug refractory on Class I-IV AADs (i.e., having VT episodes despite drug therapy)

    a. Subject must be on at least one AAD at time of enrollment

  2. Qualifying episode must be sustained, monomorphic Ventricular Tachycardia post myocardial infarction
  3. ICD implanted
  4. 1 to 3 sustained monomorphic VT episodes requiring appropriate therapy within the previous six (6) months as determined by the investigator
  5. History of myocardial infarction documented by the development of pathological Q waves with or without symptoms, imaging evidence of a region of loss of viable myocardium that is thinned and fails to contract in the absence of a nonischemic cause, or pathological findings of a healed or healing myocardial infarction
  6. 18 years or older
  7. Able and willing to comply with all pre- and follow-up testing and requirements
  8. Signed Informed Consent Form

Exclusion Criteria:

  1. Age < 18 years
  2. Documented intra-atrial or ventricular thrombus or other abnormality on preablation echocardiogram
  3. Patients with Incessant Ventricular Tachycardia (continuous sustained VTs that recur promptly despite repeated intervention for termination over several (≥ 3) hours)
  4. Contraindication to anticoagulation
  5. NYHA class IV
  6. Left ventricular assist devices (LVADs) or other circulatory assist devices
  7. Stroke as confirmed by plasma d-dimer levels or acute myocardial infarction as documented by electrocardiogram or cardiac imaging within the past three (3) months. (Note that a small cardiac enzyme release resulting from being in VT/shocks/etc. is not considered a myocardial infarction.)
  8. Patients with active ischemia who are eligible for revascularization
  9. Patients with idiopathic Ventricular Tachycardia or Ventricular Tachycardia of non-ischemic cause (such as nonischemic cardiomyopathy)
  10. Other disease process likely to limit survival to less than 12 months
  11. Serum creatinine of ≥ 2.5mg/dl
  12. Thrombocytopenia or coagulopathy
  13. Prior ablation for Ventricular Tachycardia
  14. Women who are pregnant (as evidenced by pregnancy test if pre-menopausal)
  15. Enrollment in an study evaluating an investigational device or drug
  16. Unable or unwilling to comply with protocol requirements
  17. Exclusively Polymorphic Ventricular Tachycardia
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01557842

  Show 23 Study Locations
Sponsors and Collaborators
Biosense Webster, Inc.
Study Chair: David Callans, MD University of Pennsylvania
Study Chair: Francis Marchlinski, MD University of Pennsylvania
Study Chair: Andrea Natale, MD Texas Cardiac Arrhythmia Research Foundation
Study Chair: Vivek Reddy, MD Icahn School of Medicine at Mount Sinai
Study Chair: David Wilber, MD Loyola University
  More Information

Responsible Party: Biosense Webster, Inc. Identifier: NCT01557842     History of Changes
Other Study ID Numbers: ASPIRE
Study First Received: March 16, 2012
Results First Received: December 19, 2014
Last Updated: May 13, 2017

Keywords provided by Biosense Webster, Inc.:
Ventricular Tachycardia
Implantable Cardioverter Defibrillators
Antiarrhythmic Drug Therapy

Additional relevant MeSH terms:
Tachycardia, Ventricular
Pathologic Processes
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Anti-Arrhythmia Agents processed this record on September 21, 2017